Last week, Abhijit Banerjee, Esther Duflo and Michael Kremer accepted the 2019 Nobel Memorial Prize in Economic Sciences. They were recognized for their use of randomized controlled trials, also known ...
The U.S. health care system is often inefficient, ineffective, and inequitable. Compared to other high-income countries, the U.S. pays more for health care and has worse outcomes. One potentially ...
The REPLACE-2 trial analyzed the effect of bivalirudin (Angiomax, The Medicines Company, Parsippany, New Jersey) for use during percutaneous coronary intervention (PCI). Angiomax, a small-molecule ...
Section 1115 waivers in the Medicaid program are meant to be experiments for states to test coverage approaches that don't meet federal requirements. However, most of those evaluations fall far short, ...
On March 30, 2016, in a rare moment of bipartisanship, Congress passed and the President signed an important bill creating the Commission on Evidence-Based Policymaking. The 15-person Commission, ...
Although we support Lisbeth B. Schorr’s call for a variety of evaluation methods to identify promising social programs (“Innovative Reforms Require Innovative Scorekeeping,” Aug. 26, 2009.), we ...
Editor’s note: This story was first published on Econofact. The Nobel Memorial prize in Economic Sciences awarded this year to Abhijit Banerjee, Esther Duflo, and Michael Kremer has focused attention ...
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First ...
Randomized, evidence-based trials, long required for new drugs, are now underway for government policy initiatives. By Amy Finkelstein Facing an urgent need to determine whether new coronavirus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results